Riskpilot← Back to searchSign inGet full accessMedLase Nordics AB
ABActiveOrg 5593705071Svärdvägen 29Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20225 employees
Revenue 2024
SEK 33,3M
+9% vs 2023
EBITDA margin
7.7%
+163% vs 2023
Equity ratio
53.3%
Financial strength
Net profit 2024
SEK 1,7M
+145% vs 2023
| Revenue | SEK 33,3M | +9% |
| EBITDA | SEK 2,6M | +163% |
| Net profit | SEK 1,7M | +145% |
| Total assets | SEK 6,6M | +63% |
| Equity | SEK 3,5M | +69% |
| Employees | 5 | — |
Legal name
MedLase Nordics AB
Org number
5593705071
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
15 mars 2022
Share capital
SEK 50 000
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva marknadsföring och försäljning av medicinteknisk utrustning samt därmed förenlig verksamhet.
Address
Svärdvägen 29
Email
info@medlase.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 13 182 | 13 182 | 30 657 | 33 303 |
| Staff expenses | — | −541 | — | — |
| EBITDA | 2 070 | 2 070 | 972 | 2 561 |
| Depreciation & amort. | −0 | −0 | −0 | −241 |
| EBIT | 2 070 | 2 070 | 972 | 2 320 |
| Net financials | −16 | −16 | −46 | −38 |
| Profit before tax | 2 054 | 2 054 | 927 | 2 282 |
| Tax | −434 | 434 | −232 | −582 |
| Net profit | 1 620 | 1 620 | 695 | 1 700 |
| Item | 2022 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 4 763 | 4 763 | 4 071 | 6 624 |
| Equity | 1 670 | 1 670 | 2 085 | 3 529 |
| Long-term debt | 417 | 417 | 243 | 0 |
| Short-term debt | 2 676 | 2 676 | 1 743 | 3 095 |
| Total debt | 3 093 | 3 093 | 1 986 | 3 095 |
EBITDA margin
7.7%
This company
15.8%
Market median
-51% vs market
20222024
Equity ratio
53.3%
This company
38.2%
Market median
+40% vs market
20222024
Return on equity
48.2%
This company
18.4%
Market median
+162% vs market
20222024
Net profit margin
5.1%
This company
8.1%
Market median
-37% vs market
20222024
Asset turnover
5.03×
This company
1.12×
Market median
+349% vs market
20222024
Debt / equity
0.88×
This company
0.62×
Market median
+42% vs market
20222024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-03-15 – 2022-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-03-01 – 2022-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
HA Audit | Audit | 2025 |
IH Chief Executive Officer | Chief Executive Officer | 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
| Former (3) | ||
| Deputy Board Member | 2022 – 2022 | |
| Deputy Board Member | 2022 – 2022 | |
| Board of Directors | 2022 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of MedLase Nordics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Halit Akan | Audit | 0 companies |
| Izedine Hirbli | Chief Executive Officer | 0 companies |
| Lars Hugo Viking Rillner | Deputy Board Member | 0 companies |
| Stina Maria Selldén | Deputy Board Member | 0 companies |
| Mikaela Jenni Berglund | Board of Directors | 0 companies |
| Mari-Sofi Eriksson | Deputy Board Member | 0 companies |